212 related articles for article (PubMed ID: 31843555)
21. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway.
Yao J; Xu C; Fang Z; Li Y; Liu H; Wang Y; Xu C; Sun Y
Biochem Biophys Res Commun; 2016 May; 474(1):213-219. PubMed ID: 27109471
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.
Hsieh TF; Chen CC; Ma WL; Chuang WM; Hung XF; Tsai YR; Lin MH; Zhang Q; Zhang C; Chang C; Shyr CR
Oncol Rep; 2013 Dec; 30(6):2917-22. PubMed ID: 24126741
[TBL] [Abstract][Full Text] [Related]
24. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
25. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
27. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
[TBL] [Abstract][Full Text] [Related]
28. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
29. Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
Proverbs-Singh T; Feldman JL; Morris MJ; Autio KA; Traina TA
Endocr Relat Cancer; 2015 Jun; 22(3):R87-R106. PubMed ID: 25722318
[TBL] [Abstract][Full Text] [Related]
30. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
31. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
Wu G; Sun Y; Xiang Z; Wang K; Liu B; Xiao G; Niu Y; Wu D; Chang C
Cell Death Dis; 2019 Jan; 10(2):37. PubMed ID: 30674872
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians.
Shiina M; Hashimoto Y; Kato T; Yamamura S; Tanaka Y; Majid S; Saini S; Varahram S; Kulkarni P; Dasgupta P; Mitsui Y; Sumida M; Tabatabai L; Deng G; Kumar D; Dahiya R
Oncotarget; 2017 Jan; 8(5):8356-8368. PubMed ID: 28039468
[TBL] [Abstract][Full Text] [Related]
33. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
He J; Lan X; Duan HL; Luo H; Zhou XD
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
[TBL] [Abstract][Full Text] [Related]
34. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
[TBL] [Abstract][Full Text] [Related]
37. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
38. Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signals.
Xie H; Li L; Zhu G; Dang Q; Ma Z; He D; Chang L; Song W; Chang HC; Krolewski JJ; Nastiuk KL; Yeh S; Chang C
Oncotarget; 2015 May; 6(14):12326-39. PubMed ID: 25940439
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44.
Yu G; Yao W; Xiao W; Li H; Xu H; Lang B
J Exp Clin Cancer Res; 2014 Dec; 33(1):779. PubMed ID: 25551284
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.
Ebron JS; Shukla GC
Prostate; 2016 Jun; 76(9):834-44. PubMed ID: 26988939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
